Breaking Barriers in Endocrinology: Landmark Clinical Trial Opens Islet Cell Transplants to Type 1 Diabetes Patients with Chronic Kidney Disease

Medical research has officially entered a new era for individuals managing the complex intersection of type 1 diabetes and compromised renal health. In a milestone development for endocrinology and transplant medicine, a groundbreaking clinical trial funded by Breakthrough T1D has officially launched, evaluating the efficacy of Eledon Pharmaceuticals’ targeted immunotherapy, tegoprubart, in combination with deceased-donor islet cell transplants. Most notably, this trial marks the first time in medical history that patients living with both type 1 diabetes and chronic kidney disease have been deemed eligible for an islet cell therapy clinical trial. The first participant enrolled in this multi-center study has already successfully received their transplant, signaling a monumental step forward for a patient demographic that has historically been excluded from beta-cell replacement therapies due to the severe risks of standard immunosuppressive drugs.

The Core Challenge: Navigating the Immunosuppression Dilemma

To understand the significance of this new clinical trial, one must examine the fundamental hurdles that have defined islet cell transplantation for decades. When a patient receives a transplant of insulin-producing pancreatic islet cells, the recipient’s immune system immediately recognizes the foreign tissue as a threat and attempts to destroy it. To prevent this rejection, patients must undergo powerful immunosuppressive regimens.

Historically, standard immunosuppression protocols have heavily relied on drugs such as tacrolimus, a calcineurin inhibitor. While effective at keeping the immune system at bay, tacrolimus and similar traditional agents carry severe systemic side effects. Chief among these is nephrotoxicity—the capacity to cause significant, cumulative damage to the kidneys. Furthermore, traditional immunosuppressants can exert direct toxicity on the newly transplanted islet cells, undermining the very therapy they are meant to protect.

Because of this inherent kidney toxicity, strict clinical guidelines have barred individuals with pre-existing renal impairment—such as chronic kidney disease—from participating in islet transplant trials or receiving standard cell therapies. Given that chronic kidney disease is one of the most prevalent and debilitating long-term microvascular complications associated with type 1 diabetes, this exclusion criterion created an insurmountable barrier for a massive segment of the patient population. Millions of individuals who could potentially benefit from functional cures or significant improvements in glycemic control were categorically disqualified because their kidneys could not safely process the required anti-rejection medications.

The Emergence of Tegoprubart as a Targeted Solution

Enter tegoprubart, an investigational immunotherapy engineered to offer a safer, more refined approach to preventing organ and cellular rejection. Developed by Eledon Pharmaceuticals, tegoprubart functions as a targeted immune therapy that selectively modulates the immune response without the harsh, broad-spectrum toxicity profiles associated with older immunosuppressive drugs.

By bypassing the need for calcineurin inhibitors like tacrolimus, tegoprubart aims to protect both the newly transplanted pancreatic islets and the patient’s existing kidney function. This dual-protection mechanism removes the primary pharmacological roadblock that previously prevented patients with compromised renal health from accessing cell replacement therapies.

The clinical path leading to this current milestone has been marked by rigorous scientific validation. Eledon Pharmaceuticals, operating with critical funding and partnership support from Breakthrough T1D, has been evaluating tegoprubart in an ongoing clinical trial involving deceased-donor islet cell transplants for patients suffering from severe hypoglycemic events or complete hypoglycemia unawareness—a dangerous condition where individuals lose the physiological warning signs of plummeting blood glucose levels.

Results from prior phases of this research have demonstrated remarkable promise. In those trials, participating individuals successfully achieved independence from daily insulin injections while maintaining favorable safety profiles and avoiding severe adverse side effects. Having established that this approach can effectively serve as a functional cure for uncomplicated type 1 diabetes, researchers and institutional backers turned their attention toward the next logical, yet previously restricted, frontier: patients battling both type 1 diabetes and chronic kidney disease.

Trial Design, Participant Criteria, and Institutional Execution

The newly launched clinical trial is structured as a multi-center study designed to enroll up to 10 carefully screened participants. The research is currently active across two premier medical institutions: the University of Chicago and the University of Miami, both of which possess world-class expertise in transplantation, immunology, and endocrinology.

Financial backing for the initiative is substantial, highlighted by an $8.5 million research grant awarded by Breakthrough T1D to the University of Chicago to underwrite the study. Additionally, Eledon Pharmaceuticals is recognized as a portfolio company of the T1D Fund, reinforcing the tight-knit philanthropic and venture capital ecosystem driving these next-generation therapeutics forward.

To qualify for the trial, candidates must meet specific clinical parameters, including a confirmed diagnosis of type 1 diabetes coupled with chronic kidney disease—a profile that would have disqualified them from every previous islet transplant protocol in medical history. Once enrolled, participants undergo the islet cell transplantation procedure while being maintained on a calcineurin inhibitor-free immunosuppression regimen centered around tegoprubart. This ensures that their vulnerable kidneys are shielded from tacrolimus-induced injury throughout the post-transplant recovery phase.

Measuring Success: Primary Endpoints and Follow-Up Metrics

The success of this trial will be evaluated through rigorous, standardized medical benchmarks assessed at the one-year post-transplant mark. Principal investigators and research teams will track several primary endpoints to determine the clinical viability and safety of the tegoprubart regimen:

1. Insulin Therapy Independence: Measuring the percentage of participants who are able to completely eliminate or drastically reduce their reliance on exogenous insulin injections.
2. Glycemic Control: Monitoring overall blood sugar regulation, specifically targeting sustained HbA1c levels of less than 7%.
3. Hypoglycemic Safety: Utilizing advanced continuous glucose monitoring (CGM) systems to verify the complete elimination of severe hypoglycemic episodes.
4. Renal Preservation: Assessing the stability or preservation of kidney function post-transplant, confirming that the absence of calcineurin inhibitors successfully protects against further renal decline.

Official Perspectives and Institutional Leadership

The launch of this trial represents the culmination of years of strategic planning, advocacy, and financial investment by leading medical organizations dedicated to eradicating type 1 diabetes and its complications.

Dr. Esther Latres, Senior Vice President of Research at Breakthrough T1D, emphasized the strategic importance of the initiative in a statement following the announcement of the trial’s first patient enrollment. "Advancing promising islet cell research that is a next step toward durable and scalable cures for type 1 diabetes is a key priority for Breakthrough T1D," Dr. Latres stated. "We’re proud to support this trial that expands cell therapy research and access to people living with T1D and chronic kidney disease for the first time."

The initiative forms a foundational pillar of Breakthrough T1D’s broader Project ACT initiative, a concerted global campaign designed to accelerate the clinical translation of beta-cell replacement technologies. The ultimate vision of Project ACT and its supporting organizations is to minimize or entirely eliminate the need for systemic immunosuppression, thereby transforming islet cell transplantation from a specialized procedure for a select few into a universally accessible option for anyone living with type 1 diabetes, regardless of secondary health complications.

Broader Implications and the Future of Beta-Cell Replacement

The implications of this clinical trial extend far beyond the initial cohort of 10 participants. If tegoprubart proves capable of safely supporting islet cell transplants in patients with chronic kidney disease, the medical community anticipates a paradigm shift in how endocrine disorders and organ complications are managed in tandem.

Historically, patients with advanced type 1 diabetes who experienced total kidney failure were forced to undergo simultaneous or sequential pancreas-kidney transplants—major surgical interventions associated with exceptionally high morbidity rates, long recovery times, and limited donor organ availability. Islet cell transplantation, by contrast, is a minimally invasive infusion procedure typically performed via the portal vein of the liver. Opening this pathway to patients with chronic kidney disease provides a significantly less traumatic alternative for restoring blood glucose regulation.

Furthermore, this trial aligns with a broader roadmap recently published by Breakthrough T1D detailing the systematic steps required to scale beta-cell replacement therapies for global clinical use. By solving the dual problems of immune rejection and nephrotoxic immunosuppression, researchers are moving closer to a future where functional cures for type 1 diabetes are not limited by a patient’s baseline organ health.

As the medical community monitors the progress of the first enrolled patient and awaits initial data from the University of Chicago and the University of Miami sites, the atmosphere surrounding type 1 diabetes research is one of cautious optimism. The wall that once separated vulnerable kidney patients from the promise of islet cell therapy has officially begun to crumble, opening a new chapter of hope and clinical possibility for millions worldwide.